Antiepileptic Drugs Market By Type 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Antiepileptic Drugs Market
Antiepileptic Drugs Market: By Type (First Generation Drugs, Second Generation Drugs and Pipeline Drugs); By Geography (Global, Americas, Europe, APAC and ROW) - Study With Forecast (2016-2021)
Report Code : HCR 0142
Published: 07 March, 2016   No. of pages: 135

  • Report Description
  • Table of Contents
  • Customization Options
Antiepileptic drugs are used to treat patients with epilepsy. Epilepsy is a brain disorder, which leads to a patient having seizures whenever a set of neurons send proper electrical impulses. Epilepsy has a psychological effect on patients which affects their day-to-day activities making otherwise normal day chores a challenge. The cause for epilepsy has still yet not been determined although many believe that drastic lifestyle changes have led to the onset of epilepsy across the globe. Some of these lifestyle changes include smoking, alcohol abuse, drugs abuse etc. Antiepileptic drugs are able to arrest the symptoms of epilepsy to a certain extent. The degree to which the symptoms can be spressed depends on the age of the patient, the degree to which the individual has been affected and the general body constitution of the patient. 

In terms of geographical contribution, the North American region accounts for the highest share of the antiepileptic drugs market. This is due to two main reasons, the first being that the condition of epilepsy was recognized in this region whereas in other regions such as APAC and Latin America, it was not recognized as a condition. Further to this, the level of research, which takes place for neurology is the highest in North America and as such, the reason was one of the first to bring in antiepileptic drugs. As on date, it is estimated that close to 3 million individuals in the United States alone have been recognized as having been affected by epilepsy.  The United States was one of the first few countries, which was able to utilize the second-generation antiepileptic drugs. 

Countries in Asia have now also recognized epilepsy and now possess a huge potential for the antiepileptic drug market. Countries like China, India and Thailand have a large number of cases of epilepsy that are now also being treated with antiepileptic drugs.

Antiepileptic Drugs Market 

The Antiepileptic Drugs market can be segmented on the basis of type as
First Generation Drugs:
  • Valproate (Depakote)
  • Oxycarbazepine ((Trileptal)
  • Carbamazepine (Carbatrol)
  • Phenobarbital (Luminal)
  • Primidone (Mysoline)
  • Ethosuximide (Zarontin)
  • Topiramate (Topamax)
Second Generation Drugs:
  • Lamotrigine (Lamictal)
  • Pregabalin (Lyrica)
  • Eslicarbazepine acetate Zonisamide (Zonegran)
  • Lacosamide (Vimpat)
  • Levetiracetam (Keppra)
  • (Aptiom/Zebinix) 
  • Perampanel (Fycompa)
  • Rufinamide (Banzel/Inovelon)
  • Ezogabine/retigabine (Trobalt/Potiga)
Pipeline Drugs: 
  • Buspirone
  • Everoline
  • UCB0942 (PPSI)
  • Lacosamide
  • GWP42006
  • TAK-932
  • Brivaracetam (UCB Pharma Ltd)
  • Ganaxolone (Marinus Pharmaceuticals)
  • USL261 (Upsher Smith Laboratories, Inc.)
  • Perampanel (Eisai Co) 
  • YKP3089 (SK Life Sciences) 

The market has been segmented based on the following geographies:
  • North America
  • South America
  • APAC
  • Europe
  • Middle East 
  • Africa

Following are just a few of the companies that are operating in the Antiepileptic Drugs market:
  • Abbott Laboratories
  • Cephalon
  • GlaxoSmithKline
  • Johnson & Johnson 
  • Novartis AG
1. Antiepileptic Drugs– Market Overview
2. Executive Summary 
3. Antiepileptic Drugs– Market Landscape 
   3.1. Market Share Analysis
   3.2. Comparative Analysis
      3.2.1. Product Benchmarking
      3.2.2. End User Profiling
      3.2.3. Top 5 Financials Analysis
4. Antiepileptic Drugs– Market Forces
   4.1. Market Drivers 
   4.2. Market Constraints
   4.3. Market Challenges
   4.4. Attractiveness of the Antiepileptic Drugs Market 
      4.4.1. Power of Suppliers
      4.4.2. Power of Customers 
      4.4.3. Threat of New Entrants 
      4.4.4. Threat of Substitution
      4.4.5. Degree of Competition
5. Antiepileptic Drugs Market – Strategic Analysis
   5.1. Pipe Line Analysis
   5.2. Pricing Analysis 
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Antiepileptic Drugs Market– By Type
   6.1. First Generation Drugs
      6.1.1. Valproate (Depakote)
      6.1.2. Oxycarbazepine ((Trileptal)
      6.1.3. Carbamazepine (Carbatrol)
      6.1.4. Phenobarbital (Luminal)
      6.1.5. Primidone (Mysoline)
      6.1.6. Ethosuximide (Zarontin)
      6.1.7. Topiramate (Topamax)
   6.2. Second Generation Drugs
      6.2.1. Lamotrigine (Lamictal)
      6.2.2. Pregabalin (Lyrica)
      6.2.3. Eslicarbazepine acetate Zonisamide (Zonegran)
      6.2.4. Lacosamide (Vimpat)
      6.2.5. Levetiracetam (Keppra)
      6.2.6. (Aptiom/Zebinix)
      6.2.7. Perampanel (Fycompa)
      6.2.8. Rufinamide (Banzel/Inovelon)
      6.2.9. Ezogabine/retigabine (Trobalt/Potiga)
   6.3. Pipeline Drugs
      6.3.1. Buspirone
      6.3.2. Everoline
      6.3.3. UCB0942 (PPSI)
      6.3.4. Lacosamide
      6.3.5. GWP42006
      6.3.6. TAK-932
      6.3.7. Brivaracetam (UCB Pharma Ltd)
      6.3.8. Ganaxolone (Marinus Pharmaceuticals)
      6.3.9. USL261 (Upsher Smith Laboratories, Inc.)
      6.3.10. Perampanel (Eisai Co)
      6.3.11. YKP3089 (SK Life Sciences)
   6.4. Others
7. Antiepileptic Drugs Market– By Geography
   7.1. Introduction
   7.2. Global Study
   7.3. Americas
      7.3.1. North America 
      7.3.2. Brazil
      7.3.3. Argentina
      7.3.4. Others 
   7.4. Europe
      7.4.1. U.K.
      7.4.2. France
      7.4.3. Germany
      7.4.4. Others
   7.5. APAC
      7.5.1. China
      7.5.2. Japan
      7.5.3. India
      7.5.4. Others
   7.6. ROW
8. Antiepileptic Drugs Market Entropy
   8.1. New Product Launches
   8.2. M&As, Collaborations, JVs and Partnerships
9. Company Profiles 
   9.1. Abbott Laboratories
   9.2. Cephalon
   9.3. GlaxoSmithKline
   9.4. Johnson & Johnson
   9.5. Novartis AG
   9.6. Pfizer
   9.7. Sanofi S.A
   9.8. Sunovion Pharmaceuticals
   9.9. UCB Pharma Ltd.
   9.10. Valeant Pharmaceuticals International
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
10. Appendix
   10.1. Abbreviations
   10.2. Sources
   10.3. Research Methodology
   10.4. Bibliography
   10.5. Compilation of Expert Insights
   10.6. Disclaimer
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports